VERAXA Biotech AG (VERAXA) has entered a co-discovery alliance with OmniAb, Inc. for the development of a novel bispecific antibody drug conjugate (bsADC) program targeting solid tumors. 

The collaboration combines OmniAb’s suite of transgenic antibody discovery solutions with VERAXA’s proprietary antibody drug conjugate (ADC) linker technology and conjugation expertise to support next-generation therapeutic discovery.

Under the terms of the agreement, VERAXA will initiate a novel bispecific antibody drug conjugate program addressing two attractive target molecules in cancer medicine. The company will utilize OmniAb’s suite of transgenic antibody discovery solutions to source high-quality human antibody leads, which are naturally optimized through in vivo affinity maturation. 

VERAXA will establish the bsADC lead candidate by applying its proprietary linker technology and conjugation routine. VERAXA will also be responsible for preclinical validation. 

The bsADC program will be jointly owned by both parties. Both parties will share any future revenues resulting from the program’s continued development, licensing, and commercialization.

Christoph Antz, Ph.D., CEO and Co-Founder of VERAXA, commented, “Bispecific ADCs represent a powerful opportunity to address difficult-to-treat solid tumors, and this collaboration fits squarely within our mission to drive innovation through targeted partnerships. Strategic collaborations will continue to be a mainstay in VERAXA’s pipeline growth strategy, and today’s announcement marks the second major initiative within the past six months, following our first radiopharmaceutical alliance late last year. We look forward to advancing this discovery program alongside OmniAb and deliver novel therapeutic solutions for patients with significant unmet needs.”